Year: 2019

Not for distribution to U.S. newswire services for dissemination in the United States of America. Any failure to comply with this restriction may constitute a violation of U. S. securities law.TORONTO, Dec. 30, 2019 (GLOBE NEWSWIRE) — Stratabound Minerals Corp. (TSXV: SB) (“Stratabound” or “the Company”) is pleased to announce that Mr. Terrence Byberg has been appointed Interim Chairman of the Board and that Ms. Christina Wu has been appointed as Chief Financial Officer of the Company.Mr. Byberg has been a Director of the Company since May, 2016  and will continue to serve as Executive Vice President of Stratabound, a position he has held since October 2017.   Mr. Byberg has served as a Director of a number of other corporate boards and has forty-three years of international mining experience...

BARRIE, Ontario, Dec. 30, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in research-driven, pharmaceutical quality cannabis extraction, distillation and derivative product production, today announced that its subsidiary, MediPharm Labs Inc. (“MediPharm”) has received a licence amendment from Health Canada allowing for production to begin in the recently expanded area of its specialized manufacturing facility in Barrie, Ontario.This amendment increases MediPharm’s licensed facility footprint by around three times, or 16,746 sq. ft., to a total of approximately 25,000 sq. ft., allowing it to productively use more of its manufacturing space for cannabis activities – including automated downstream...

London United Kingdom – 30 December 2019 – With great sadness Cyber Security 1 AB (Publ) (Nasdaq First North Growth Market: CYB1) announces that Kobus Paulsen, Founder and Chairman and Major Shareholder, unexpectedly passed away on Sunday.The company extends its sincerest condolences to his family in this difficult time and express their deepest felt and enduring gratitude for his leadership and inspiration.Effective immediately, the board of directors has commenced with the process to implement its succession plan with further details to be announced as appropriate. “An outstanding leader and visionary, Kobus will be remembered for his energy and drive and most importantly for being a devoted husband, father and friend. We all will miss his tremendous presence in our lives.” said executive board member...

FREDERICTON, New Brunswick, Dec. 30, 2019 (GLOBE NEWSWIRE) — Trius Investments Inc. (TSXV:TRU.H) (“Trius”) announces that Peter K. Deacon has resigned from its board of directors, effective as of December 31, 2019, in order to focus on his other business interests in 2020, and particularly River Birch Global Water Inc. where he serves as President and Chief Executive Officer. Mr. Deacon has volunteered to remain available to Trius on a transitional basis to advise on strategic and transactional matters.Joel Freudman, President and Chief Executive Officer of Trius, commented, “We thank Peter for serving as an independent director of Trius since late 2017. He has been a valuable voice on our board as we navigated restructuring activities and reverse takeover plans, and we wish him the best of luck expanding River Birch...

SHANGHAI, China, Dec. 30, 2019 (GLOBE NEWSWIRE) — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced that it has priced its initial public offering of 11,500,000 American depositary shares (“ADSs”) at a price to the public of US$5.38 per ADS for a total offering size of approximately US$61.87 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents three Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Stock Market today under the ticker symbol “MKD.”The Company has granted to the underwriters an option, exercisable within 30 days from the date of the final prospectus,...

NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the first patient has been dosed in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology.HB-201 is a TheraT® platform-based vector (replication attenuated) from the arenavirus family expressing a non-oncogenic but highly antigenic E6/E7 fusion protein from HPV16. In preclinical studies, HB-201 was observed to be highly immunogenic, resulting in a robust CD8+ T cell response as compared to...

Í viðhengi má finna áætlun Landsbankans um fjármögnun á markaði fyrir árið 2020.ViðhengiFjármögnunaráætlun 2020

Attached is a schedule of Landsbankinn‘s market funding for the year 2020.AttachmentFunding plan 2020

SALT LAKE CITY, Dec. 30, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza® (olaparib).  Lynparza is marketed by AstraZeneca (LSE/OMX Nordic/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.  BRACAnalysis CDx is the first and only FDA-approved genetic test for this indication.“The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing...

All co-primary endpoints achieved in both Phase 3 clinical trialsTwyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over timeAdditional data to be shared during the January 8th investor conference call and webcastNESS ZIONA, Israel, Dec. 30, 2019 (GLOBE NEWSWIRE) —  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an investigational, combination of microencapsulated tretinoin 0.1% and microencapsulated benzoyl peroxide 3% cream, which demonstrated statistically significant improvement on all co-primary endpoints in the treatment of patients with acne vulgaris. Twyneo was also found to be well-tolerated.The primary endpoints for both trials included: the proportion of patients who succeeded...